First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease
A review published in Prescrire International (2013) evaluated first-line treatments for metastatic prostate cancer, focusing on androgen suppression therapies like orchiectomy and gonadorelin agonists, which provide significant pain relief for about 80% of patients with bone metastases. However, the effect of these therapies on overall survival remains uncertain. Nonsteroidal antiandrogen